vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Below 50 Day Moving Average – Time to Sell?

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $35.86 and traded as low as $32.90. vTv Therapeutics shares last traded at $33.72, with a volume of 46,095 shares changing hands.

Analysts Set New Price Targets

Several research analysts recently commented on VTVT shares. Evercore started coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a report on Wednesday, March 11th. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Zacks Research upgraded shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Trading Down 0.4%

The stock has a market cap of $131.40 million, a P/E ratio of -35.86 and a beta of 0.26. The firm’s fifty day moving average is $35.74 and its 200 day moving average is $34.89.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, topping the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. Research analysts forecast that vTv Therapeutics Inc. will post -2.19 earnings per share for the current fiscal year.

Institutional Trading of vTv Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VTVT. Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter worth $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the 4th quarter worth $731,000. Geode Capital Management LLC grew its position in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its position in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.